China’s deadly coronavirus vaccine COVID-19 has undergone its first trials and has produced promising results
This is reported by The Lancet Medical Journal.
Studies have shown that the drug is safe, well tolerated and able to cause an immune response to the virus. The first phase of the trial was conducted 28 days with the participation of 108 healthy adults. The final results of the Chinese vaccine trial will be announced in six months.
“The challenges in developing a vaccine against COVID-19 are unprecedented, and the ability to induce an immune response does not necessarily mean that the vaccine can protect people from infection. The results offer a promising prospect for the development of a COVID-19 vaccine, but we are still far from making such a vaccine available to all,” said Professor Chen Wei of the Institute of Biotechnology in Beijing.